Analysis of the Discontinuation of Protease Inhibitor Therapy in Routine Clinical Practice

References

• Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. N Engl J Med 1996; 335: 1081–90.
   PubMed Web of Science ®Google Scholar
• Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4 + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997; 126: 929–38.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–60.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725–30.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Smith M, Holodniy M, Kahn J. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277: 145–53.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–8.
   PubMed Web of Science ®Google Scholar
• Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423–31.
   PubMed Web of Science ®Google Scholar
• Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665–70.
   Google Scholar
• Rhone SA, Hogg RS, Yip B, Sherlock Ch, Conway B, Schechter MT, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998; 12: 619–24.
   PubMed Web of Science ®Google Scholar
• Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke Ch, Becker K, et al. Virologic treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11: F113–6.
   Google Scholar
• Mocroft A, Gill MJ, Davidson W, Philips AN. Predictors of a viral response and subsequent virological failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12: 2161–7.
   PubMed Web of Science ®Google Scholar
• Wit FWNM, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year followup of a cohort of human immunodeficiency virus type 1-in-fected persons. J Infect Dis 1999; 179: 790–8.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863–8.
   PubMed Web of Science ®Google Scholar
• O’Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD, VA Cooperative Study Group on AIDS. Changes in plasma HIV RNA levels and CD4 + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997; 126: 939–45.
   Google Scholar
• Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, Shevitz AH, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992; 92: 495–502.
   PubMed Web of Science ®Google Scholar
• Singh N, Squier C, Hayes P, Wagener MM, Sivek C, Goetz A, et al. Determinants of compliance in patients with HIV: prospective assessment with implications for enhancing compliance. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, October 1994, Abstract I–170.
   Google Scholar
• Tebas P, Royal M, Fichtenbaum C, Blutman J, Arens M, Horgan M, et al. Relationship between adherence to HAART and disease state. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998, Abstract 149.
   Google Scholar
• Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice. 5th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998, Abstract 151.
   Google Scholar
• Shelton MJ, Esch LD, Hewitt RG, Cousins S, Morse GD. The impact of patient-reported adherence with antiretroviral therpay on virologic response. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998, Abstract I–170.
   Google Scholar
• Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528–33.
   PubMed Web of Science ®Google Scholar
• Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tija FJ, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29–33.
   PubMed Web of Science ®Google Scholar
• Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in. Updated recommendations of the International AIDS Society-USA panel. JAMA 1998; 280: 78–86.
   Google Scholar
• Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA 1997; 278: 63–5.
   PubMed Web of Science ®Google Scholar
• Tuldra A, Ferrer MJ, Rodriguez C, Bayes R, Burger D, Clotet B. A proposed model to predict compliance with antiretroviral therapy. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998, Abstract I–177.
   Google Scholar
• Burger DM, Hugen PWH, Prins JM, Van de Ende ME, Reiss P, Lange JMA. Pharmacokinetics of an Indinavir/Ritonavir 800/100 mg BID regimen. 6th Conference on Retroviruses and Opportunistic Infections; Chicago: January 31–February 4, 1999, Abstract 363.
   Google Scholar
• Johnson M, Petersen A, Winslade J, Clendeninn N. Comparison of bid and tid dosing of viracept in combination with stavudine and lamivudine. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998, Abstract 373.
   Google Scholar
• Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998; 279:930–7.
   PubMed Web of Science ®Google Scholar
• Katlama C, Murphy R, Johnson V, Squires K, Horban A, Gatell J, et al. The Atlantic Study: A randomized open-label study comparing two protease inhibitors-sparing antiretroviral strategies vs. a standard PI-containing regimen. 6th Conference on Retroviruses and Opportunistic Infections; Chicago: January 31–February 4, 1999, Abstract 18.
   Google Scholar
• Morales-Ramirez J, Tashima K, Hardy D, Johnson P, Nelson M, Staszewski S, et al. A phase II, multi-center randomized, open label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + Lamivudine (3TC), versus IDV + 3TC at > 36 weeks [DMP 266–006]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998, Abstract I–103.
   Google Scholar
• Havlir D, Mc Laughlin MM, Richman DD. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3. AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995; 172: 1379–83.
   Google Scholar